BOSTON, MA / ACCESSWIRE / March 27, 2024 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) provided a corporate update today announcing a strategy to maximize its ability to capture the potential ...

Pieris are easy-to-grow and cold-hardy evergreen shrubs with dark fingered foliage that is attractive all year round. This plant (also known as the andromeda bush or the lily-of-the-valley bush) ...

Pieris' PIRS shares were up almost 8% after it announced that it will receive an undisclosed milestone payment from partner Boston Pharmaceuticals related to its pipeline candidate, BOS-342 (formerly ...

Pieris Pharmaceuticals’ long-standing immuno-oncology alliance with Servier is being dissolved after a clinical trial of the lead drug in the alliance revealed a safety concern. In a Securities & ...

AstraZeneca has sailed away from a licensing deal for Pieris Pharmaceuticals’ asthma med, forcing the biotech to begin charting a new corporate course and lay off 70% of its staff in the process. The ...

My first spring catalog has come. The excitement at our house is at a winter high — thinking of all of the green that comes with spring and the opportunities to add to my landscape. I have marked ...

AstraZeneca has pulled the plug on clinical trials of its asthma candidate elarekibep after seeing data from a toxicology study. Pieris Pharmaceuticals, which licensed the inhaled IL-4 receptor alpha ...

Pieris Pharmaceuticals Inc PIRS shares are trading higher after the company provided a strategic update. The company says the update follows recent events that have impacted its inhaled respiratory ...

US biotech Pieris Pharmaceuticals has begun a collaboration and supply agreement with Eli Lilly, trialling its cancer drug PRS-343 in combination with the big pharma’s Cyramza (ramucirumab). PRS-343 ...

Pieris Pharmaceuticals’ PIRS shares were up almost 12% on Jul 18, after management announced strategic update in light of the recent events that have impacted its respiratory franchise. In order to ...